Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

M
MacDonald, Alexander

Allucent
(W-080) Comparison of common methodologies for accounting for IIV for oral bioavailability (F) in the absence of intravenous data
Alexander MacDonald
Favorite
Madrigal, Jamie

UNC Chapel Hill
(M-071) Mechanistic mathematical model of emicizumab
Jamie Madrigal
Favorite
Măgălie, Andreea

Merck & Co
(W-081) Quantifying dengue natural immunity and probability of disease using serum antibody titers
Andreea Măgălie
Favorite
Ma, Huilin

Bristol Myers Squibb
(T-083) Application of quantitative systems pharmacology modeling in reverse translation
Huilin Ma
Favorite
Mai, Tu

Genentech Inc.
(W-082) Population Pharmacokinetic and Exposure-Response Analyses of Alectinib and Its Metabolite M4 to Support Dose Selection in Patients with Resected Stage IB - IIIA ALK-Positive Non-Small Cell Lung Cancer
Tu Mai
Favorite
Mangal, Naveen

Gilead Sciences
(W-083) Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Naveen Mangal
Favorite
Mapder, Tarunendu

Bristol Myers Squibb
(M-072) A shared pool modeling approach to describe antibody-mediated cell-cell interactions
Tarunendu Mapder
Favorite
Matteson, Andrew

Certara
(M-073) A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation
Andrew Matteson
Favorite
Matzuka, Brett

Regeneron Pharmaceuticals, Inc.
(T-026) A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Brett Matzuka
Favorite
Ma, Xiaotang (Jessica)

Bristol-Myers Squibb
(M-070) Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose
Xiaotang (Jessica) Ma
Favorite
Mc Laughlin, Anna

Pharmetheus
(M-074) Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Anna Mc Laughlin
Favorite
McKnite, Autumn

University of Utah
(T-084) A COMBINED EX VIVO AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC APPROACH TO INCORPORATE DRUG-DRUG INTERACTIONS FOR DOSING DURING CONTINUOUS RENAL REPLACEMENT THERAPY
Autumn McKnite
Favorite
Meaney, Cameron

Simulations Plus
(T-085) Modeling progression and treatment of mCRPC using the Thales QSP software platform
Cameron Meaney
Favorite
Mehrani, Ramin

Merck & Co Inc
(W-084) Exploring the feasibility of using AI to identify patient characteristics predictive of histological endpoints in metabolic dysfunction associated steatohepatitis (MASH)
Ramin Mehrani
Favorite
Mehta, Parsshava

University of Florida
(W-085) The Influence of Systematic and Technical Errors on Population Pharmacokinetic / Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach
Parsshava Mehta
Favorite
Mensing, Sven

AbbVie
(M-075) Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
Sven Mensing
Favorite
Mercier, Francois

Clinical Pharmacology, Genentech Inc., Basel, Switzerland
(T-016) Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
Francois Mercier
Favorite
Metelkin, Evgeny

InSysBio CY
(W-006) Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Evgeny Metelkin
Favorite
Milberg, Oleg

Regeneron Pharmaceuticals, Inc.
(M-076) Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)
Oleg Milberg
Favorite
Miyazawa, Kenji

Moderna, Inc.
(T-086) Development of a Whole-Body Physiologically Based Pharmacokinetics (PBPK) Model for Predicting Dynamics of mRNA and Protein for LNP-Encapsulated mRNA Therapeutics
Kenji Miyazawa
Favorite
Modi, Saurabh

Clinical Pharmacology Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA
(W-086) Prediction of progression free survival using tumor growth inhibition models: Effect of model uncertainty, inter-individual variability and observational noise on prediction accuracy
Saurabh Modi
Favorite
Moein, Anita

Genentech, Inc.
(M-077) Population Pharmacokinetic Analysis of Fenebrutinib in Patients with Relapsing Multiple Sclerosis
Anita Moein
Favorite
Mohan, Krithika

GSK
(M-078) PKPD Modeling of PROTACs
Krithika Mohan
Favorite
Morales Junior, Ronaldo

Cincinnati Children's Hospital
(T-087) Population pharmacokinetics of cefepime in critically ill children and young adults
Ronaldo Morales Junior
Favorite
Morales, Juan

Critical Path Institute
(M-079) Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach
Juan Morales
Favorite
Mukker, Jatinder Kaur

EMD Serono, Billerica, MA, USA
(T-063) Advancing Modeling of Hematologic Safety using a Semi-mechanistic Multivariate PK/PD Approach: Application to the ATR Inhibitor Tuvusertib in Early Phase Oncology Development
Jatinder Kaur Mukker
Favorite